I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| plasmablast | 6 studies | 48% ± 22% | |
| epithelial cell | 6 studies | 23% ± 8% | |
| T cell | 6 studies | 51% ± 12% | |
| erythrocyte | 6 studies | 40% ± 27% | |
| CD8-positive, alpha-beta T cell | 6 studies | 52% ± 20% | |
| natural killer cell | 6 studies | 51% ± 23% | |
| B cell | 5 studies | 32% ± 9% | |
| hematopoietic precursor cell | 5 studies | 34% ± 22% | |
| transit amplifying cell | 5 studies | 34% ± 7% | |
| pro-B cell | 5 studies | 40% ± 16% | |
| endothelial cell | 4 studies | 19% ± 2% | |
| progenitor cell | 4 studies | 32% ± 17% | |
| erythroblast | 4 studies | 62% ± 18% | |
| megakaryocyte-erythroid progenitor cell | 4 studies | 44% ± 24% | |
| CD4-positive, alpha-beta T cell | 4 studies | 67% ± 7% | |
| conventional dendritic cell | 3 studies | 23% ± 10% | |
| abnormal cell | 3 studies | 24% ± 3% | |
| neural crest cell | 3 studies | 43% ± 20% | |
| plasma cell | 3 studies | 39% ± 14% | |
| precursor B cell | 3 studies | 50% ± 22% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 44% ± 13% |
